A bacterial extracellular vesicle‐based intranasal vaccine against SARS‐CoV‐2 protects against disease and elicits neutralizing antibodies to wild‐type and Delta variants

Показати інші версії (1)

Several vaccines have been introduced to combat the coronavirus infectious disease‐2019 (COVID‐19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Current SARS‐CoV‐2 vaccines include mRNA‐containing lipid nanoparticles or adenoviral vectors that encode the SARS‐CoV‐...

Повний опис

Бібліографічні деталі
Автори: Jiang, Linglei, Driedonks, Tom A.P., Jong, Wouter S.P., Dhakal, Santosh, Bart van den Berg van Saparoea, H., Sitaras, Ioannis, Zhou, Ruifeng, Caputo, Christopher, Littlefield, Kirsten, Lowman, Maggie, Chen, Mengfei, Lima, Gabriela, Gololobova, Olesia, Smith, Barbara, Mahairaki, Vasiliki, Riley Richardson, M., Mulka, Kathleen R., Lane, Andrew P., Klein, Sabra L., Pekosz, Andrew, Brayton, Cory, Mankowski, Joseph L., Luirink, Joen, Villano, Jason S., Witwer, Kenneth W.
Формат: Online Стаття Текст
Мова:English
Опубліковано: John Wiley and Sons Inc. 2022
Предмети:
Research Articles
Онлайн доступ:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920961/
https://www.ncbi.nlm.nih.gov/pubmed/35289114
http://dx.doi.org/10.1002/jev2.12192

Інтернет

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920961/
https://www.ncbi.nlm.nih.gov/pubmed/35289114
http://dx.doi.org/10.1002/jev2.12192

Схожі ресурси